As in the CSF-1R blocking antibody experiments (Fig. 4A–D), blocking tumor-derived CSF-1 inhibited TMEM doorway activity, increased vascular integrity, and decreased dissemination of tumor cells as CTCs (Fig. 5A–E). The gene discussed is CSF1R; the disease is neoplasm.